Clinical trialNCT03534323Active, not recruitingPhase 1/PHASE2Interventional

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

SponsorDana-Farber Cancer InstituteEnrollment55Chronic Lymphocytic LeukemiaRichter Syndrome

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Matthew S Davids, MD
Dana-Farber Cancer Institute
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Miami- Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Northern Light Eastern Maine Medical Center
Brewer, Maine, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Boston Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Berkshire Medical Center
Pittsfield, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Duvelisib →Venetoclax →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Jul 2018
Primary completion: 1 Dec 2024
Completion: 1 Jul 2026
Last update posted: 23 Mar 2026
Registered enrollment: 55
Registry id: NCT03534323

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.